Graded Insulin Suppression Test P&F
Human Models of Selective Insulin Resistance: Graded Insulin Suppression Test (GIST) Pilot & Feasibility Study
Columbia University
15 participants
Sep 16, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. Participants will be asked to come in for a one-day study visit in which they will undergo a "graded insulin suppression test" ("GIST"). The GIST involves intravenous (into the vein) infusions of octreotide, a medication that turns off the body's own production of insulin, as well as replacement of insulin at two different levels (low and high), with or without replacement of glucagon, and glucose (sugar). The study investigators will check blood sugar levels every few minutes during the procedure to determine the effect of the two different insulin levels. This study will evaluate the GIST in both healthy volunteers and those at higher risk for type 2 diabetes.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Insulin infusion to recapitulate euinsulinemia (normal basal insulin)
Insulin infusion to induce hyperinsulinemia for assessment of insulin sensitivity
Suppression of endogenous insulin secretion
Production of steady-state plasma glucose (SSPG) reflective of insulin sensitivity at hyperinsulinemia
Replacement of endogenous glucagon suppressed by octreotide. (Use is optional at the PI's discretion.)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06592261